IRIS
BOSSI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 8.677
NA - Nord America 6.832
SA - Sud America 1.650
EU - Europa 938
AF - Africa 167
OC - Oceania 7
Totale 18.271
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.509
SG - Singapore 5.577
BR - Brasile 1.334
CN - Cina 1.333
VN - Vietnam 731
HK - Hong Kong 301
IT - Italia 290
IN - India 156
CA - Canada 152
GB - Regno Unito 127
AR - Argentina 121
DE - Germania 119
MX - Messico 111
BD - Bangladesh 99
FR - Francia 64
ZA - Sudafrica 58
TR - Turchia 57
ID - Indonesia 52
EC - Ecuador 51
ES - Italia 50
IQ - Iraq 46
PL - Polonia 42
JP - Giappone 39
RU - Federazione Russa 38
VE - Venezuela 35
CO - Colombia 34
UA - Ucraina 34
NL - Olanda 32
MY - Malesia 31
PK - Pakistan 30
UZ - Uzbekistan 29
MA - Marocco 28
CL - Cile 24
NP - Nepal 23
SE - Svezia 23
SA - Arabia Saudita 22
KE - Kenya 20
JO - Giordania 18
PY - Paraguay 18
TN - Tunisia 18
PH - Filippine 17
AE - Emirati Arabi Uniti 15
FI - Finlandia 15
JM - Giamaica 14
UY - Uruguay 14
EG - Egitto 13
IE - Irlanda 12
AT - Austria 11
LT - Lituania 11
IR - Iran 10
TH - Thailandia 10
BE - Belgio 9
KZ - Kazakistan 9
PE - Perù 9
TW - Taiwan 9
BA - Bosnia-Erzegovina 8
CR - Costa Rica 8
OM - Oman 8
CH - Svizzera 7
IL - Israele 7
AL - Albania 6
DZ - Algeria 6
ET - Etiopia 6
HN - Honduras 6
RO - Romania 6
AM - Armenia 5
AU - Australia 5
BY - Bielorussia 5
GE - Georgia 5
HR - Croazia 5
NI - Nicaragua 5
RS - Serbia 5
AZ - Azerbaigian 4
BH - Bahrain 4
BO - Bolivia 4
CZ - Repubblica Ceca 4
HU - Ungheria 4
KR - Corea 4
LB - Libano 4
PR - Porto Rico 4
PS - Palestinian Territory 4
SN - Senegal 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
BB - Barbados 3
BG - Bulgaria 3
CI - Costa d'Avorio 3
CY - Cipro 3
DO - Repubblica Dominicana 3
GY - Guiana 3
PA - Panama 3
QA - Qatar 3
SR - Suriname 3
AO - Angola 2
BW - Botswana 2
GA - Gabon 2
GD - Grenada 2
KW - Kuwait 2
LK - Sri Lanka 2
MM - Myanmar 2
Totale 18.246
Salva come PNG Salva come JPEG
Città #
Singapore 2.256
San Jose 1.502
Ashburn 1.260
The Dalles 920
Dallas 532
Shanghai 527
Beijing 307
Ho Chi Minh City 282
Hong Kong 277
Santa Clara 180
Los Angeles 176
Hanoi 158
New York 150
Buffalo 114
São Paulo 110
Seattle 90
Assago 62
Orem 48
Milan 46
Mexico City 45
Montreal 45
Johannesburg 41
Chicago 38
Rio de Janeiro 38
Atlanta 37
Boardman 37
Warsaw 36
Curitiba 34
Munich 34
San Francisco 31
Tokyo 31
Brooklyn 30
Da Nang 30
Charlotte 29
Naples 29
Haiphong 28
Tashkent 28
Council Bluffs 27
Campinas 26
London 26
Toronto 25
Belo Horizonte 24
Chennai 24
Frankfurt am Main 24
Phoenix 23
Brasília 21
Stockholm 21
Boston 19
Denver 19
Manchester 19
Guayaquil 18
Mumbai 18
Nairobi 18
Ribeirão Preto 18
Secaucus 18
New Delhi 17
Dhaka 16
Kuala Lumpur 16
Quito 16
Amsterdam 15
Baghdad 15
Rome 15
Istanbul 14
Poplar 14
Santiago 14
Amman 13
Biên Hòa 13
Goiânia 13
Bogotá 12
Buenos Aires 12
Caracas 12
Chandler 12
Hải Dương 12
Pasadena 12
Porto Alegre 12
Tunis 12
Ankara 11
Dublin 11
Fortaleza 11
Karachi 11
Montevideo 11
Paris 11
Salvador 11
Hangzhou 10
Helsinki 10
Houston 10
Juneau 10
Las Vegas 10
Vancouver 10
Bengaluru 9
Hillsboro 9
Jeddah 9
Kingston 9
Ottawa 9
Santo André 9
Sorocaba 9
Asunción 8
Betim 8
Bến Tre 8
Cairo 8
Totale 10.525
Salva come PNG Salva come JPEG
Nome #
New trends in supportive care of head and neck cancers 118
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis 111
Ectopic olfactory neuroblastoma is associated with increased frequency of syndrome of inappropriate antidiuretic hormone secretion and reduced disease control: Case series with systematic review and pooled analysis 105
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy 99
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck 95
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer 95
Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer 93
Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck 85
Improving the multidisciplinary therapeutic management of head and neck squamous cell carcinoma: Consensus statements from an Italian expert panel 80
Dietary intervention for tertiary prevention in head and neck squamous cell carcinoma survivors: clinical and translational results of a randomized phase II trial 78
Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials 78
Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents 78
Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology 76
Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study 75
A pilot study of a smartphone-based monitoring intervention on head and neck cancer patients undergoing concurrent chemo-radiotherapy 75
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6 74
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy 71
A case of otoliquorrhoea secondary to immunotherapy response in head and neck cutaneous squamous cell carcinoma. When abrupt response may worry the physician 70
The Interplay between Age and Viral Status in EBV-Related Nasopharyngeal and HPV-Related Oropharyngeal Carcinoma Patients 69
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact 69
A ct-based radiomic signature can be prognostic for 10-months overall survival in metastatic tumors treated with nivolumab: An exploratory study 69
Computer Vision Foundation Models in Endoscopy: Proof of Concept in Oropharyngeal Cancer 68
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab 67
Role of Radiotherapy in the management of metastases from salivary gland carcinoma. 67
M. D. Anderson symptom inventory head neck (MDASI-HN) questionnaire: Italian language psychometric validation in head and neck cancer patients treated with radiotherapy ± systemic therapy – A study of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) 66
USO DI MIRNA COME BIOMARCATORI PER LA DIAGNOSI E PROGNOSI DEL CARCINOMA ORALE A CELLULE SQUAMOSE 66
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 65
International, Multi-Institutional Evaluation of Practice Patterns and Outcomes for Recurrent and Metastatic Sinonasal Undifferentiated Carcinoma 63
A randomized, double-blind, placebo controlled, phase II study to evaluate the efficacy of ginseng in reducing fatigue in patients treated for head and neck cancer 63
Phase IV study on the use of benzydamine mouthwash in radiation-induced oral mucositis in patients with head and neck cancer 63
Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial 61
ESMO Guidelines: Cancer patient management during the COVID-19 pandemic 61
Understanding Protective Mechanisms of an Oral Probiotic in Reducing Radiation-Induced Oral Mucositis 58
Financial toxicity questionnaire (FIT): development and validation of the italian version (FITALY) in head and neck cancer patients undergoing multimodal curative treatment 57
Is precision medicine the solution to improve organ preservation in laryngeal/hypopharyngeal cancer? A position paper by the Preserve Research Group 57
The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers 56
Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real-World Data From 17 Italian Centers 56
A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes 56
A European survey on the practice of nutritional interventions in head–neck cancer patients undergoing curative treatment with radio(chemo)therapy 55
A complete remission with androgen-deprivation therapy in a recurrent androgen recptor-expressing adenocarcinoma of the parotid gland [1] 55
A randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy of Aqualief™ mucoadhesive tablets in head and neck cancer patients who developed radiation-induced xerostomia 55
Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life 54
A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients 54
The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports 53
A NATURAL HISTORY OF A SERIES OF RADIOACTIVE IODINE (131I-RAI)-RESISTANT ADVANCED DIFFERENTIATED THYROID CANCER (DTC) 53
Functional profiles of curatively treated adenoid cystic carcinoma unveil prognostic features and potentially targetable pathways 52
Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods 52
Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic 52
Updated perspectives on the contribution of the microbiome to the pathogenesis of mucositis using the MASCC/ISOO framework 52
Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort 52
A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches 52
The use of fentanyl in pain management in head and neck cancer patients: a narrative review 52
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy 51
Sinonasal Malignancies of Anterior Skull Base Histology-driven Treatment Strategies 51
Immune checkpoint inhibitor in high-risk oral potentially malignant disorders (IMPEDE study): An interim analysis on safety 51
Nutritional Support in Cancer patients: update of the Italian Intersociety Working Group practical recommendations 51
Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer? 51
The Use of Artificial Intelligence in Head and Neck Cancers: A Multidisciplinary Survey 51
Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis 51
Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients 50
Overview of oral potentially malignant disorders: From risk factors to specific therapies 50
Editorial: Understanding and treating rare nasal and paranasal sinus cancers 50
Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma 50
Muscle quality and not quantity as a predictor of survival in head and neck squamous cell carcinoma 50
Expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: A bi-institutional retrospective concordance analysis (CONCORDL-1 study) 50
Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer 50
Health care-associated infections (HAIs) in head and neck carcinoma (HNC) patients treated with chemotherapy (CT) and/or radiotherapy (RT) 50
Role of TORS as De-Escalation Strategy in HPV-Related Oropharyngeal Cancer, What We Need to Know 49
FURTHER IMPROVEMENT IN OUTCOMES OF NASOPHARYNGEAL CARCINOMA WITH OPTIMIZED RADIOTHERAPY AND INDUCTION PLUS CONCOMITANT CHEMOTHERAPY: AN UPDATE OF THE MILAN EXPERIENCE 49
New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma 49
Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines 49
Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines 49
Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines - part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents 49
Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer 48
The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures 48
Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial 48
Quality Assessment in Supportive Care in Head and Neck Cancer 48
Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies? 47
Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma 47
Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data 47
Prevalence of Fatigue in Head and Neck Cancer Survivors 47
RANK expression in EBV positive nasopharyngeal carcinoma metastasis: A ready-to-treat target? 47
Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment 47
The predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis 47
Stability of circulating miRNA in saliva: The influence of sample associated pre-analytical variables 47
Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy 47
Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up 47
The vicious circle of treatment-induced toxicities in locally advanced head and neck cancer and the impact on treatment intensity 47
Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area 47
The Evolving Role of Systemic Therapy in the Primary Treatment of Sinonasal Cancer 47
Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus 46
Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines-part 1: vitamins, minerals, and nutritional supplements 46
Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up 46
The 2024 International Society of Oral Oncology-Multinational Association of Supportive Care in Cancer-American Society of Clinical Oncology guidelines for the prevention and management of osteoradionecrosis of the jaw 46
A multidisciplinary approach to squamous cell carcinomas of the head and neck: What is new? 46
Precision medicine in head and neck cancer: from immunotherapy to microbiota, circulating DNA and robotic surgery 46
The SINTART 2 Study. A phase II non-randomised controlled trial of induction chemotherapy, photon-, proton- and carbon-ion-based radiotherapy integration in patients with locally advanced unresectable sinonasal tumours 46
Nodal status in major salivary gland cancer: External validation of a novel N- classification 46
Diving into hot topics of salivary gland carcinoma management—an EORTC young and early career investigator survey 46
What to do and what not to do in the management of cancer pain: A physician survey and expert recommendations 46
Totale 5.870
Salva come PNG Salva come JPEG
Categoria #
all - tutte 108.175
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.175
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 0 0 0 0 2
2021/20224 0 0 0 2 0 0 0 1 0 0 1 0
2022/202334 4 0 2 4 5 3 0 1 11 2 1 1
2023/20241.254 2 2 6 0 0 0 1 434 43 53 251 462
2024/20254.244 138 26 56 86 45 395 214 189 825 1.141 533 596
2025/202613.224 1.797 902 705 992 466 739 3.790 616 681 988 799 749
Totale 18.770